Korean biotech IPOs Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
01:09
Apr 30
Apr 30
Quality Korean biotech IPOs offer opportunities.
The speaker sees opportunity in Korean biotech IPOs. 2025 listings have generally delivered better returns and maintain market caps above KRW 500bn; stricter technology-special listing standards since 2022 mean listed companies are higher quality and more likely to survive. Many 2026 IPO candidates also have strong track records, so new IPOs are expected to lead KOSDAQ biotech over the medium term.
HIGH
About Korean biotech IPOs Investor Commentary
Across the available history and selected sources, Buzzberg tracks Korean biotech IPOs across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kim Seon-ah.